[DRNA] Dicerna Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 65.71 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.2 Change: 0.15 (4.92%)
Ext. hours: Change: 0 (0%)

chart DRNA

Refresh chart

Strongest Trends Summary For DRNA

DRNA is in the long-term up 360% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company?s development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including hemophilia, porphyria, hypercholesterolemia, hemoglobinopathies, alpha-1-antitrypsin deficiency hepatocyte, inclusions, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated, as well as a product candidate targeting the oncogene KRAS; and a second product candidate targeting an oncogene. The company has a research collaboration and license agreement with Kyowa Hakko Ki

Fundamental Ratios
Shares Outstanding20.73 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV0.76 Price/Cash Per Share0.75
Price/Free Cash Flow-1.79 ROA-55.23% ROE-59.06% ROI
Current Ratio14.81 Quick Ratio Long Term Debt/Equity Debt Ratio0.07
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities150 K Cash From Investing Activities7.07 M Cash From Operating Activities-10.65 M Gross Profit
Net Profit-14.08 M Operating Profit-14.14 M Total Assets92.75 M Total Current Assets89.09 M
Total Current Liabilities6.02 M Total Debt Total Liabilities6.02 M Total Revenue
Technical Data
High 52 week15.9 Low 52 week9.67 Last close15 Last change2.25%
RSI55.63 Average true range0.82 Beta1.5 Volume169.43 K
Simple moving average 20 days3.8% Simple moving average 50 days5.69% Simple moving average 200 days13.6%
Performance Data
Performance Week7.53% Performance Month4.68% Performance Quart0.2% Performance Half3.09%
Performance Year13.38% Performance Year-to-date40.32% Volatility daily2.33% Volatility weekly5.21%
Volatility monthly10.69% Volatility yearly37.02% Relative Volume366.28% Average Volume405.27 K
New High New Low

News

2019-11-15 12:30:12 | Drug giant Roche acquires Lexington biotech for $390M

2019-11-13 16:05:00 | Dicerna™ to Present at the Stifel 2019 Healthcare Conference

2019-11-08 19:12:12 | Edited Transcript of DRNA earnings conference call or presentation 7-Nov-19 9:30pm GMT

2019-11-07 16:05:00 | Dicerna™ Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress

2019-11-04 07:30:00 | Dicerna™ to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019

2019-11-01 20:06:00 | Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-11-01 07:38:56 | The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

2019-10-31 06:30:00 | Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B

2019-10-31 06:30:00 | Dicerna™ Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis B Virus HBV Infection

2019-10-28 16:13:51 | Is Dicerna Pharmaceuticals Inc DRNA A Good Stock To Buy?

2019-10-28 10:32:02 | Dicerna Pharmaceuticals DRNA May Report Negative Earnings: Know the Trend Ahead of Q3 Release

2019-10-01 16:30:00 | Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-09-25 16:05:00 |  Dicerna™ to Present at Two Upcoming Investor Conferences

2019-09-19 16:05:00 | Dicerna™ Appoints Patrick Gray to Board of Directors to Support Continued Growth

2019-09-16 07:58:58 | How Should Investors Feel About Dicerna Pharmaceuticals, Inc.'s NASDAQ:DRNA CEO Pay?

2019-09-04 16:05:00 | Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-09-03 16:05:00 | Dicerna™ to Present at H.C. Wainwright 21st Annual Global Investment Conference

2019-09-03 03:20:51 | 3 Biopharma Stocks With Over 50% Upside

2019-08-28 15:16:47 | Is Arrowhead Pharmaceuticals Inc ARWR’s Recently Published U.S. Patent Application A Blockbuster?

2019-08-15 09:00:38 | BioBoyScout’s Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals ARWR

2019-08-09 20:05:28 | Dicerna Pharmaceuticals Inc DRNA Q2 2019 Earnings Call Transcript

2019-08-09 18:49:27 | Edited Transcript of DRNA earnings conference call or presentation 8-Aug-19 8:30pm GMT

2019-08-08 16:05:00 | Dicerna™ Reports Second Quarter 2019 Financial Results and Provides Corporate Update

2019-08-02 16:05:00 | Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-08-01 16:05:00 | Dicerna™ to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019

2019-07-31 13:48:03 | Steven Cohen Charges Into Chiasma

2019-07-15 07:30:00 | Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1 PH1

2019-07-07 11:19:29 | 5 Stocks With Over 20% Upside Potential, Say Top Analysts

2019-07-02 07:00:00 | Dicerna™ to Begin Clinical Development of DCR-A1AT for Treatment of Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

2019-07-02 07:00:00 | RNAi startup Dicerna developing new liver drug

2019-07-01 16:30:00 | Dicerna™ Reports Inducement Grant Under Nasdaq Listing Rule 5635c4

2019-06-21 07:30:00 | Dicerna™ Presents Additional Data from PHYOX™1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 PH1 and Type 2 PH2

2019-06-20 07:30:00 | Globally Recognized Nephrologist Joins Dicerna™ to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria

2019-06-18 11:45:21 | Did The Underlying Business Drive Dicerna Pharmaceuticals's NASDAQ:DRNA Lovely 393% Share Price Gain?

2019-06-13 07:30:00 | Dicerna™ Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy

2019-06-12 16:04:01 | Bain's second life sciences fund comes in over $1 billion

2019-06-11 18:57:08 | Here’s What Hedge Funds Think About Dicerna Pharmaceuticals Inc DRNA

2019-06-04 07:30:00 | Dicerna™ Appoints Rob Ciappenelli Chief Commercial Officer

2019-06-03 16:30:00 | Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-05-28 16:05:00 | Dicerna™ to Present at the Jefferies 2019 Healthcare Conference

2019-05-16 07:30:00 | Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus

2019-05-10 18:09:38 | Edited Transcript of DRNA earnings conference call or presentation 9-May-19 8:30pm GMT

2019-05-09 21:24:08 | Dicerna Pharmaceuticals Inc DRNA Q1 2019 Earnings Call Transcript

2019-05-09 19:15:11 | Dicerna Pharmaceuticals DRNA Reports Q1 Loss, Lags Revenue Estimates

2019-05-09 18:07:21 | Dicerna Pharmaceuticals: 1Q Earnings Snapshot

2019-05-09 16:05:00 | Dicerna™ Reports First Quarter 2019 Financial and Operating Results and Provides Corporate Update

2019-05-07 11:47:24 | Hedge Funds Have Never Been More Bullish On Dicerna Pharmaceuticals Inc DRNA

2019-05-03 16:05:00 | Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-05-02 16:05:00 | Dicerna™ to Report First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019

2019-05-02 07:30:00 | Dicerna™ Submits Updated IND Application for DCR-PHXC for Treatment of Primary Hyperoxaluria PH for the PHYOX™2 Pivotal Trial